UMIN ID: C000000018
Registered date:04/07/2005
Phase I study of SMILE chemotherapy for advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma/leukemia(NK-SMILE-P1)
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | extranodal NK/T-cell lymphoma, nasal type or cytological diagnosis of aggressive NK-cell leukemia according to the WHO Classification |
Date of first enrollment | 2005/07/01 |
Target sample size | 24 |
Countries of recruitment | Japan,Asia(except Japan) |
Study type | Interventional |
Intervention(s) | Two cycles of SMILE chemotherapy consisting from steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide. |
Outcome(s)
Primary Outcome | maximum tolerated dose (MTD) |
---|---|
Secondary Outcome | the overall response rate and the complete response rate. |
Key inclusion & exclusion criteria
Age minimum | 15years-old |
---|---|
Age maximum | 69years-old |
Gender | Male and Female |
Include criteria | |
Exclude criteria | (1)Previous history of stem cell transplantation (2)Skin as the only affected site of involvement (3)Clinical symptoms of CNS involvement (CSF cytology or brain MRI imaging are not required) (4)Need for radiation more than 15 Gy including palliation at the time of registration (5)History of serious adverse reaction(s) by agents including SMILE chemotherapy (Example: allergy for L-asparaginase, delayed excretion of methotrexate, etc.) (6)Pleural effusion or ascites except for those with little amount, which cannot be performed pleural or abdominal puncture (7)Uncontrollable hypertension (8)History of myocardial infarction or angina, cardiomyopathy, or arrhythmia under drug treatment (9)HBs antigen positive (10)HIV antibody positive (11)Accompanying interstitial pneumonitis, pulmonary fibrosis, or severe emphysema (all apparently diagnosed by chest X-ray) (12)Severe infections (13)Liver cirrhosis, either biopsy proven or clinically diagnosed (14)Active double cancer: overlapping cancer or asynchronous cancer within 5 years. Carcinoma in situ, intramucosal cancers, and other equivalent lesions are not included for the active double cancer. (15)Women during pregnancy, lactation period or of childbearing potentials not using a reliable contraceptive method (16)Use of major tranquilizer, antidepressant, or antimanic (17)Severe psychosis |
Related Information
Primary Sponsor | NK-cell Tumor Study Group |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Kirin Brewery Co., LTD. |
Secondary ID(s) |
Contact
public contact | |
Name | |
Address | Japan |
Telephone | |
nkktumor-group@umin.ac.jp | |
Affiliation | NK-cell Tumor Study Group NK-cell Tumor Study Group |
scientific contact | |
Name | Kazuo Oshimi |
Address | Hongo, Bunkyo-ku, Tokyo 113-8421, Japan Japan |
Telephone | |
Affiliation | Juntendo University Department of Hematology |